CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $54.66M, above the global median of $18.73M
- FinancialsAltman Z-Score 2.55: grey zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.23BCNY929.65M · vs all stocks (USD)
Revenue (TTM)
2.46BCNY367.18M · vs all stocks (USD)
Profit Margin
-10.91%vs Biotechnology peers
Beta
0.6390xvs all stocks
52-Week Change
-41.78%vs all stocks
Market Capitalization
6.23BCNY929.65M · vs all stocks (USD)
Enterprise Value
4.97BCNY741.48M · vs all stocks (USD)
Forward P/E
33.52xvs Biotechnology peers
Price to Sales (TTM)
2.45xvs Biotechnology peers
Price to Book (MRQ)
1.86xvs Biotechnology peers
Enterprise to Revenue
2.02xvs Biotechnology peers
Gross Margin
54.69%vs Biotechnology peers
Profit Margin
-10.91%vs Biotechnology peers
Operating Margin
-4.63%vs Biotechnology peers
Return on Assets (TTM)
-2.27%vs Biotechnology peers
Return on Equity (TTM)
-8.79%vs Biotechnology peers
Revenue (TTM)
2.46BCNY367.18M · vs all stocks (USD)
Revenue per Share (TTM)
5.61CNYUpdated Sep 22, 2026Quarterly Revenue Growth
6.00%vs Biotechnology peers
Gross Profit (TTM)
1.27BCNY189.82M · vs all stocks (USD)
EBITDA (TTM)
23.74MCNY3.54M · vs all stocks (USD)
Net Income (TTM)
-268.46MCNY-40.07M · vs all stocks (USD)
Operating Cash Flow (TTM)
357.03MCNY53.29M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
366.20MCNY54.66M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-5.00MCNYFY2025 · Dec 31, 2025Revenue
2.45BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.22BCNYFY2025 · Dec 31, 2025Gross Profit
1.23BCNYFY2025 · Dec 31, 2025Operating Income
-193.66MCNY-28.91M · vs all stocks (USD)
Pre-tax Income
-237.05MCNYFY2025 · Dec 31, 2025Income Tax Expense
37.76MCNYFY2025 · Dec 31, 2025Net Income
-274.82MCNYFY2025 · Dec 31, 2025EBIT
-215.40MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
23.74MCNYFY2025 · Dec 31, 2025Research & Development
441.21MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
759.45MCNYFY2025 · Dec 31, 2025Other Operating Expenses
52.30MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
8.86MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
21.65MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
-274.82MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
12.43MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
258.91MCNYFY2025 · Dec 31, 2025Free Cash Flow
124.24MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
996.53MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-274.82MCNYFY2025 · Dec 31, 2025Other Non-cash Items
26.25MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
208.19MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
299.29MCNYFY2025 · Dec 31, 2025Capital Expenditures
-134.67MCNYFY2025 · Dec 31, 2025Purchase of Investments
-969.00MCNYFY2025 · Dec 31, 2025Sale of Investments
623.72MCNYFY2025 · Dec 31, 2025Other Investing Activity
10.29MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-469.66MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
122.52MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-203.12MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-23.24MCNYFY2025 · Dec 31, 2025Other Financing Charges
-8.22MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-112.05MCNYFY2025 · Dec 31, 2025Shares Outstanding
450.00MSharesUpdated Sep 22, 2026Float Shares
261.63MSharesUpdated Sep 22, 2026% Held by Insiders
47.87%vs all stocks
% Held by Institutions
5.92%vs all stocks
Total Cash (MRQ)
1.34BCNY199.46M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.01CNYUpdated Sep 22, 2026Total Debt (MRQ)
617.06MCNY92.11M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1935xvs Biotechnology peers
Current Ratio (MRQ)
1.98xvs Biotechnology peers
Book Value per Share (MRQ)
7.22CNYUpdated Sep 22, 2026Total Assets
5.20BCNY776.14M · vs all stocks (USD)
Total Current Assets
2.59BCNYFY2025 · Dec 31, 2025Total Liabilities
1.89BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.61BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
212.06MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.68BCNYFY2025 · Dec 31, 2025Cash
996.52MCNYFY2025 · Dec 31, 2025Cash Equivalents
24.08MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.02BCNYFY2025 · Dec 31, 2025Other Short-term Investments
397.81MCNYFY2025 · Dec 31, 2025Accounts Receivable
486.88MCNYFY2025 · Dec 31, 2025Inventory
465.11MCNYFY2025 · Dec 31, 2025Accounts Payable
605.12MCNYFY2025 · Dec 31, 2025Short-term Debt
526.82MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.80MCNYFY2025 · Dec 31, 2025Long-term Debt
81.33MCNYFY2025 · Dec 31, 2025Common Stock (Book)
450.00MCNYFY2025 · Dec 31, 2025Retained Earnings
120.69MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.31BCNY494.12M · vs all stocks (USD)
Treasury Stock
100.02MCNYFY2025 · Dec 31, 202552-Week Low
11.29CNYUpdated Sep 22, 202652-Week High
32.12CNYUpdated Sep 22, 202652-Week Change
-41.78%vs all stocks
Beta
0.6390xvs all stocks
50-Day MA
13.15CNYUpdated Sep 22, 2026200-Day MA
18.27CNYUpdated Sep 22, 2026Avg 10-Day Volume
10.41MSharesUpdated Sep 22, 2026Avg 30-Day Volume
17.31MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-0.6100CNYUpdated Sep 22, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Where is this company structurally exposed?
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.55Profit Margin: -0.11
Financial Health
Altman Z-Score 2.55: grey zoneSignificant
Altman Z-Score: 2.55
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $54.66M, above the global median of $18.73MNotable
Levered free cash flow (USD): 54,662,382.625Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Guizhou Bailing Group Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Medincell SA
Tier 1ProductionApproval-Gated PipelineRule
R&G Pharmastudies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Cybin Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Alumis Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
KPC Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jade Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bioventus Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Beijing Tong Ren Tang Chinese Medicine Company Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
UFP Industries, Inc.
2 interpretationsIndustry-Benchmarked Return on Capital ElevatedDown-Close Share With Multi-Year Earnings Decrease
Zhejiang Jiahua Energy Chemical Industry Co., Ltd.
2 interpretationsIndustry-Benchmarked Return on Capital ElevatedDown-Close Share With Multi-Year Earnings Decrease
LB Group Co., Ltd.
1 interpretationDown-Close Share With Multi-Year Earnings Decrease